Philadelphia, Pennsylvania–(Newsfile Corp. – January 9, 2025) – If you held shares of Akero Therapeutics, Inc. (NASDAQ: NASDAQ: ) prior to September 13, 2022, you can seek corporate reforms, a refund to the company, and a court-approved monetary award at no cost. whatever. We encourage you to learn more about the investigation and your rights by visiting https://grabarlaw.com/the-latest/akero-shareholder-investigation/. You can also contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.
WHY: A recently filed joint securities fraud lawsuit alleges that Akero Therapeutics, through certain of its officers and directors, made false and/or misleading statements and/or failed to disclose to the investing public that: (i) approximately 20% of the patients enrolled in the study SYMMETRY had cryptogenic cirrhosis and no definite NASH at baseline; (ii) patients with cryptogenic cirrhosis enrolled in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definite NASH; (iii) results from patients with cryptogenic cirrhosis should have been excluded from the calculation of the secondary end points of NASH resolution; (iv) Akero introduced a confounding factor into the design of the SYMMETRY study, materially affecting the potential results of the study and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not comply with US Food and Drug Administration guidelines for investigating a drug in the treatment of NASH cirrhosis because Akero did not rule out possible causes of cirrhosis in each patient other than NASH; and (vi) consequently, Akero materially misrepresented the nature of the SYMMETRY trial, its utility in supporting any new drug application, the likelihood that the SYMMETRY trial would be successfully measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhosis.
Law firm Grabar is investigating whether certain officers and directors of Aker violated their fiduciary duties to the company.
WHAT YOU CAN DO NOW: Current Aker shareholders who held Aker shares on or before September 13, 2022 can seek corporate reforms, a return of funds spent on defending the litigation back to the company and a court-approved incentive award, at no cost to them.
If you want to know more about this issue, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/contact Joshua Grabar at jgrabar@grabarlaw.com or call us at 267-507-6085.
$AKRO #Akero
Attorney Advertising Disclaimer
To view the original version of this press release, visit https://www.newsfilecorp.com/release/236647
